Franklin Resources Inc. Has $124.21 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Franklin Resources Inc. lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,118,688 shares of the specialty pharmaceutical company’s stock after buying an additional 48,708 shares during the quarter. Franklin Resources Inc.’s holdings in Jazz Pharmaceuticals were worth $124,208,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. LSV Asset Management grew its position in shares of Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after buying an additional 99,705 shares during the period. Pacer Advisors Inc. grew its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares during the period. Baupost Group LLC MA grew its position in shares of Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock worth $136,000,000 after buying an additional 440,552 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Jazz Pharmaceuticals by 48.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock worth $130,447,000 after buying an additional 398,549 shares during the period. Finally, Thompson Siegel & Walmsley LLC grew its holdings in Jazz Pharmaceuticals by 8.3% during the third quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock valued at $87,035,000 after purchasing an additional 59,685 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,753 shares of company stock worth $816,289 over the last ninety days. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $123.04 on Monday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The company has a market cap of $7.44 billion, a P/E ratio of 17.33, a P/E/G ratio of 1.02 and a beta of 0.57. The firm’s fifty day moving average price is $117.39 and its two-hundred day moving average price is $112.22. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research reports. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday. Finally, TD Cowen lowered their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.